Table 2.
Pharmacokinetic parameters of treprostinil in SSc patients following dose escalation to 2 mg and 4 mg BID.
| Cohort Regimen |
Statistics | Cmax (pg/mL) |
tmax (hour) |
AUC(0-12) (hr*pg/mL) |
t½ (hour) |
|---|---|---|---|---|---|
|
2 mg BID
(Number = 17) |
GeoMean CV% Median Mean CVb% Minimum Maximum |
1,063 51.1 1,190 1,176 43.6 428 2,200 |
na na 4.0 3.58 74.3 0.0 12.0 |
6,400 56.9 6,764 7,187 45.2 2027 13,820 |
2.94 61.6 3.28 3.39 56.0 1.07 8.48 |
|
4 mg BID
(Number = 12) |
GeoMean CV% Median Mean CVb% Minimum Maximum |
1,895 52.8 1,930 2,107 46.3 752 3,950 |
na na 4.0 3.67 31.5 2.0 6.0 |
11,880 45.0 11,530 12,922 43.1 6726 24,150 |
3.19 55.8 2.88 3.62 55.1 1.74 7.75 |
BID, twice daily; CV%, coefficient of variation for geometric mean, CVb%, coefficient of variation for mean; GeoMean, geometric mean; na, not applicable; SSc, systemic sclerosis.